ClearPoint Neuro Inc Dossier - Source-backed chat

ClearPoint Neuro Inc

CLPTNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.18

Intrinsic Value $12.58median of 2 methodsbased on filings through 30 Jun 2026

Market Price $11.45Price as of 1 Oct 2026

Near fair valueIntrinsic value is 10% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $349.3M

Enterprise Value $370.1M

Shares Outstanding 30.2M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ClearPoint Neuro, Inc. (CLPT) is transitioning from a niche neurosurgical navigation hardware provider into a high-margin, platform-based enabler of direct-to-brain drug delivery, cell therapies, and gene therapies. By embedding its proprietary SmartFlow cannula and navigation software into the clinical trials of over 60 biopharma partners, ClearPoint is building a powerful regulatory moat. Once a partner's therapy is approved, ClearPoint's disposable devices become the mandated delivery mechanism, creating a highly recurring, high-margin revenue stream. While near-term unprofitability and cash burn remain risks, the company's strong balance sheet ($35.6M cash as of Q1 2026 plus access to additional debt) and robust top-line growth (43% Y/Y in Q1 2026) support a speculative Buy recommendation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$25.00

Mean target$28.33

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$10.0025%

Regulatory setbacks or clinical trial failures among key biopharma partners severely impact the long-term outlook for the drug delivery segment. Slower hospital adoption of the navigation platform and integration friction with the IRRAflow product line limit 2026 revenue to under $50M. Elevated cash burn forces a dilutive equity raise in early 2027.

Base CaseCentral scenario

$20.0060%

ClearPoint delivers on its full-year 2026 revenue guidance of $52M–$56M, driven by steady expansion of its installed base to over 200 centers and continued clinical trial progress with biopharma partners. Operating expenses remain elevated due to the IRRAS integration, but cash runway remains sufficient (supported by $35.6M cash and Oberland Capital debt facility) to avoid dilutive equity financing before partner commercial revenues begin to scale in 2027-2028.

Bull CaseUpside scenario

$30.0025%

Rapid commercialization of partnered gene therapies (such as PTC Therapeutics' KEBILIDI) and successful integration of the IRRAflow neurocritical care portfolio drive revenue growth above the high end of 2026 guidance ($56M+). Gross margins expand past 65% due to manufacturing efficiencies, and operational cash burn decreases significantly, putting the company on a clear path to cash-flow neutrality by late 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Powerful regulatory moat: ClearPoint's delivery devices are written into FDA drug approval filings, making substitution virtually impossible for approved therapies.
Diversified 'shots on goal': Over 60 active biopharma partners across 25+ clinical trials mitigate the risk of any single trial failure.
Expanding product ecosystem: Recent FDA clearances (Velocity Alpha MR High Speed Drill) and acquisitions (IRRAS neurocritical care) expand the addressable market per procedure.

Key Investment Risks

Dependence on partner success: Revenue scaling is highly dependent on the clinical and regulatory success of third-party biotech therapies.
High cash burn: The company remains unprofitable, with an $8.0 million operational cash burn in Q1 2026.
Neurosurgery capital constraints: Hospital adoption of the core navigation system can be slowed by tight capital budgets and specialized MRI suite requirements.

Thesis Invalidation Triggers

Multiple late-stage clinical trial failures or regulatory rejections of key partnered CNS gene therapies.
Failure to achieve projected cost and revenue synergies from the IRRAS acquisition, leading to prolonged elevated operating expenses.
A significant acceleration in cash burn that exhausts the current cash runway before late 2027 without alternative non-dilutive funding.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.